BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

DRAGONFLY THERAPEUTICS, INC. — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Termination (No Activity)

DRAGONFLY THERAPEUTICS, INC.

via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)

3rd Quarter (July 1 - Sep 30) · 2024Posted Oct 17, 2024Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: DRAGONFLY THERAPEUTICS, INC.
Description: Clinical-stage biopharmaceutical company
Location: Massachusetts · United States of America

Registrant

Firm: FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
Description: Legislative and public affairs firm.
Location: Washington, District of Columbia, United States of America

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.